For the Inventor, By the Inventor

Enter assignee name

Eisai Company, Limited

USPTO Granted Patents = 677

CIPO Patents = 1

Trademarks = 6

Forward Citations = 7,077

Loading Chart...

Loading Chart...

983 inventors (with patents filed for the assignee):

Isao Yamatsu (83 out of 84 patents)

Shinya Abe (77 out of 134 patents)

Takeshi Suzuki (47 out of 56 patents)

4. Hiroyuki Yoshimura (42 out of 44 patents)

5. Yoshimasa Machida (41 out of 42 patents)

6. Shigeru Souda (40 out of 43 patents)

7. Norio Minami (37 out of 41 patents)

8. Shuhei Miyazawa (35 out of 40 patents)

9. Shigeto Negi (33 out of 38 patents)

10. Shigeki Hibi (32 out of 37 patents)

11. Seiichiro Nomoto (29 out of 32 patents)

12. Takashi Yamanaka (27 out of 27 patents)

13. Katsuya Tagami (27 out of 30 patents)

14. Yuichi Inai (27 out of 27 patents)

15. Naoyuki Shimomura (27 out of 31 patents)

Core Competencies:

Hemiasterlin Derivatives

Macrocyclic Compounds

Gene Therapy

Triazolone Derivatives

Cognitive Impairments

Jun Kinase Inhibitors

Heterocyclic Compounds

Toll-Like Receptor

Cholinesterase Inhibitors

Pharmaceutical Formulations

Diagnostic Agents

Cancer Treatment

677 patents: Sort by Forward Citations

1. 8633224 - Hemiasterlin derivatives and uses thereof in the treatment of cancer (2014-01-21),

2. 8329742 - Macrocyclic compounds useful as pharmaceuticals (2012-12-11),

3. 8071085 - Primary cultured adipocytes for gene therapy (2011-12-06),

4. 7999090 - Fungal cell wall synthesis gene (2011-08-16),

5. 7928228 - Triazolone derivatives (2011-04-19),

6. 7915306 - Macrocyclic compounds useful as pharmaceuticals (2011-03-29),

7. 7816522 - Triazolone derivatives (2010-10-19),

8. 7799827 - Macrocyclic compounds useful as pharmaceuticals (2010-09-21),

9. 7585976 - Hemiasterlin derivatives and uses thereof (2009-09-08),

10. 7563808 - Methods for treating cognitive impairments or dementia (2009-07-21),

11. 7528152 - Hemiasterlin derivatives and uses thereof in the treatment of cancer (2009-05-05),

12. 7445892 - Method of testing anticancer agent-sensitivity of tumor cells (2008-11-04),

13. 7390797 - Fused indazole compounds (2008-06-24),

14. 7390793 - Micelles (2008-06-24),

15. 7390490 - Uses of anti-CX3CR1 antibody, anti-fractalkine antibody and fractalkine (2008-06-24),

Eisai Company, Limited is a leading global pharmaceutical company headquartered in Japan. Established in 1941, Eisai is focused on discovering and developing innovative treatments for a range of diseases, including cancer, neurological disorders, and gastrointestinal disorders. With a mission to give first thought to patients and their families, Eisai is committed to improving healthcare outcomes and enhancing the quality of life for people worldwide.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

677 Patents

#131 in Tokyo

#299 in Japan

#1,437 in the World

Eisai Company, Limited

Forward Citations = 7,077

983 inventors:

Isao Yamatsu (83 out of 84 patents)

Shinya Abe (77 out of 134 patents)

Takeshi Suzuki (47 out of 56 patents)

4. Hiroyuki Yoshimura (42 out of 44 patents)

5. Yoshimasa Machida (41 out of 42 patents)

Please report any incorrect information to support@idiyas.com

Loading…